Growth hormone treatment after experimental myocardial infarction nearly doubled the increase in cardiomyocyte width and reduced collagen I accumulation by 50%, improving LV function.
RCT (n=140)
Does growth hormone improve cardiac remodeling and function in rats following experimental myocardial infarction?
Growth hormone administration early after experimental myocardial infarction in rats enhances cardiomyocyte hypertrophy, reduces adaptive fibrosis, and improves systolic and diastolic LV function.
OBJECTIVES: Growth hormone (GH) causes cardiomyocyte hypertrophy without development of fibrosis in the normal rat heart. The aim of this study was to evaluate the effects of GH on cardiac remodeling following experimental myocardial infarction (MI). METHODS: Following ligation of the left coronary artery or sham operation, rats were randomized to receive 2 IU GH/kg/day or vehicle for four weeks (n = 140). Extracellular matrix proteins were assessed in the non-infarcted myocardium of the posterior wall using immunohistochemistry and automatic image analysis. In addition, cardiomyocyte size was measured. RESULTS: Compared to sham, vehicle-treated rats with moderate (20-40%) and large (> 40%) infarct size showed left ventricular (LV)-dilatation, reduced fractional shortening as well as increases in LV end-diastolic and right atrial pressures, LV/body weight (BW) ratio and LV posterior wall thickness. Compared to vehicle-treated MI-rats, treatment with GH considerably increased fractional shortening and attenuated LV-dilatation. Vehicle-treated MI-rats displayed progressive increases in cardiomyocyte width and deposition of collagen I, compared to sham rats. Treatment with GH nearly doubled the increase in cardiomyocyte width and reduced collagen I accumulation by 50%. CONCLUSIONS: Our study demonstrates that GH, given early after large MI, elicits a unique pattern of structural effects characterized by enhanced cardiomyocyte hypertrophy and reduced adaptive fibrosis. This attenuation of pathological remodeling translates into a significant improvement in systolic and diastolic LV-function.
Daniela Grimm (Sun,) conducted a rct in experimental myocardial infarction (n=140). Growth hormone (GH) vs. vehicle was evaluated on Extracellular matrix proteins and cardiomyocyte size. Growth hormone treatment after experimental myocardial infarction nearly doubled the increase in cardiomyocyte width and reduced collagen I accumulation by 50%, improving LV function.